Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

REMEVi vs TrueMe

REMEVi
Graded #108

Higher grade

vs+3
TrueMe
Graded #171

Lower grade

The verdict

REMEVi takes it — 70.4/100 to 67.4/100.

REMEVi grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTrueMe +7
54
61
Dose & formulationTrueMe +13
64
77
Clinical oversightREMEVi +8
86
78
Labs & monitoringREMEVi +13
65
52
FulfillmentREMEVi +16
97
81
Contract termsREMEVi +24
69
45
REMEVi · left barTrueMe · right bar

The numbers

MetricREMEViTrueMe
WeighScore70.4/10067.4/100
GradeCC
Scorecard rank#108#171
Semaglutide$199/mo (starting dose, compounded)$159/mo (compounded)
Tirzepatide$269/mo (starting dose, compounded)$189/mo (compounded)
CoverageAll 50 states6 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
REMEVi

Graded #108 · C

Strengths

  • The first bilingual GLP-1 clinic — care delivered in English and Spanish by clinicians trained in both, not auto-translated
  • Compounded semaglutide from $199/mo and tirzepatide from $269/mo on the 52-week plan, with the same price every month (no titration price hikes)
  • LegitScript-certified and licensed in all 50 states + DC, with an NPI-verified pharmacy and overnight shipping
  • Transparent all-inclusive pricing with no hidden fees and cancel anytime; full legal suite (Privacy, Terms, HIPAA, Refund)

Where it loses points

  • Lowest pricing requires a 52-week commitment — month-to-month is higher ($279 semaglutide / $339 tirzepatide)
  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy or Zepbound
  • The specific compounding pharmacy is not named (described as 'NPI-verified')
  • A newer, patient-founded clinic; press mentions (Fortune, AP, Reuters) are syndicated PR, not editorial endorsements
TrueMe

Graded #171 · C

Strengths

  • One price covers consultation, medication, shipping, supplies and provider support, and the site states there are no separate membership fees
  • Same price at every dose, so the cost does not climb as a provider titrates the dose upward
  • Full pricing is published up front — no intake form is required before you can see what you will pay
  • Carries a genuine LegitScript-issued seal (ID 50205625) that resolves on LegitScript's own asset host
  • Names its telehealth platform (Telegra) and physician network (Strive), and the returns address names CarePoint Infusion Pharmacy in Stafford, Texas

Where it loses points

  • Serves only six states (AZ, CO, MO, PA, TX, WI), far narrower coverage than most national GLP-1 telehealth
  • Prices marketed per month are charged every 4 weeks at checkout — 13 charges a year, not 12
  • You pay before completing the medical intake, and approval is not guaranteed at the moment you are charged
  • The 3-month rates ($119 and $139/mo) are a single upfront charge of $357 or $417, not a lower monthly plan
  • A Featured In strip shows CNN, Fox News, Forbes, New York Times and NPR logos with no linked coverage

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard